Objectives Clinical heterogeneity is a cardinal feature of systemic sclerosis (SSc). Hallmark SSc autoantibodies ... Moreover, we show that antitopoisomerase-1 antibodies and anti-RNA polymerase III ...

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...

New research highlights how multimorbidity significantly worsens survival and physical function in patients with systemic ...

By targeting the RNA-dependent RNA polymerase (RdRp) sequence, it can identify over 10 5 viral species, facilitating viral monitoring and research using existing transcriptomic datasets. This ...

Amyotrophic lateral sclerosis (ALS) is a disease that destroys the nerves necessary for movement. About 30,000 people in the ...

Amyotrophic lateral sclerosis (ALS) is a disease that destroys the nerves necessary for movement. About 30,000 people in the United States are affected, and doctors still don't know what causes it. To ...

Amyotrophic lateral sclerosis (ALS) is a disease that destroys the nerves necessary for movement. About 30,000 people in the United States are affected, and doctors still don't know what causes it.

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...